No headlines found.
Globe Newswire (Tue, 2-Apr 7:00 PM ET)
Globe Newswire (Tue, 26-Mar 7:00 PM ET)
Globe Newswire (Wed, 20-Mar 7:00 PM ET)
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Medicinova trades on the NASDAQ stock market under the symbol MNOV.
As of April 23, 2024, MNOV stock price climbed to $1.36 with 5,860 million shares trading.
MNOV has a beta of 0.28, meaning it tends to be less sensitive to market movements. MNOV has a correlation of 0.01 to the broad based SPY ETF.
MNOV has a market cap of $66.70 million. This is considered a Micro Cap stock.
In the last 3 years, MNOV stock traded as high as $5.09 and as low as $1.26.
The top ETF exchange traded funds that MNOV belongs to (by Net Assets): VXF, IWC, DFAC, AVSC.
MNOV has underperformed the market in the last year with a price return of -37.9% while the SPY ETF gained +24.2%. MNOV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.3% and -8.7%, respectively, while the SPY returned +4.9% and -2.6%, respectively.
MNOV support price is $1.29 and resistance is $1.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNOV stock will trade within this expected range on the day.